http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201306848-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2901e694724c2a759f619944cb7d2a4 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 |
| filingDate | 2012-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2afb4d5bc6b955cb885692df496fdb32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0e59a1f784c7ded8e1e397ddd9547d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8cf39dbcfbbbc03610ccb67f04af07f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c93365419d934898e3cb85a12093e3de |
| publicationDate | 2013-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201306848-A |
| titleOfInvention | Seromorapin (SEMULOPARIN) for prevention of venous thromboembolism in cancer patients undergoing chemotherapy |
| abstract | The present invention relates to an ultra low molecular weight heparin having an average molecular weight of from 2000 to 3000 Daltons, an anti-FXa activity of about 160 U/mg and an anti-FIIa activity of about 2 U/mg (specifically, semuloparin) As an antithrombotic agent, it is used to prevent venous thromboembolism in cancer patients undergoing chemotherapy for locally advanced or metastatic solid tumors, more specifically for locally advanced or metastatic pancreatic cancer or Lung cancer, or patients receiving chemotherapy with locally advanced or metastatic solid tumors with a VTE risk score equal to or greater than 3. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114974592-A |
| priorityDate | 2011-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 97.